|Bid||7.27 x 900|
|Ask||25.58 x 800|
|Day's range||24.73 - 25.84|
|52-week range||11.04 - 26.99|
|Beta (5Y monthly)||1.40|
|PE ratio (TTM)||N/A|
|Earnings date||06 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.00|
Bioventus (NASDAQ: BVS) is a company that specializes in developing innovations in biologics and clinical therapies for active healing. In February of this year, Bioventus opened its doors of ownership to the public by way of an IPO of 8 million shares. Leading up to the spin-off, Smith & Nephew was experiencing strong growth from the biologics and clinical therapies unit, with annual revenue growing from $52 million in 2004 to $223 million in 2010 for that unit alone.
Good afternoon, ladies and gentlemen, and welcome to the second-quarter 2021 earnings conference call for Bioventus Inc. [Operator instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly after the end of the call. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission including Item 1A of the company's Form 10-K for the year ended December 31, 2020, as well as our most recent 10-Q filing to be filed with the Securities and Exchange Commission.
NEW ORLEANS, July 31, 2021--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Misonix, Inc. (NasdaqGS: MSON) to Bioventus Inc. (Nasdaq: BVS). Under the terms of the proposed transaction, shareholders of Misonix may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix that they own. KSF is seeking to dete